Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial

被引：0
作者：
Dae Hyun Kim
Curtis Tatsuoka
Zhengyi Chen
Jackson T. Wright
Michelle C. Odden
Srinivasan Beddhu
Brandon K. Bellows
Adam Bress
Thaddeus Carson
William C. Cushman
Karen C. Johnson
Donald E. Morisky
Henry Punzi
Leonardo Tamariz
Song Yang
Lee-Jen Wei
机构：
[1] Hinda and Arthur Marcus Institute for Aging Research,Department of Population and Quantitative Health Sciences
[2] Hebrew SeniorLife,Department of Neurology
[3] Case Western Reserve University,Department of Medicine, University Hospitals Cleveland Medical Center
[4] Case Western Reserve University,Department of Epidemiology and Population Health
[5] Case Western Reserve University,Department of Medicine
[6] Stanford University,Department of Medicine
[7] University of Utah School of Medicine,Department of Population Health Sciences
[8] Columbia University,Department of Medicine
[9] University of Utah School of Medicine,Department of Preventive Medicine
[10] Medical College of Georgia,Department of Community Health Sciences
[11] The University of Tennessee Health Science Center,Division of Population Health and Computational Medicine, Miller School of Medicine
[12] UCLA Fielding School of Public Health,Office of Biostatistics Research
[13] Punzi Medical Center,Department of Biostatistics
[14] University of Miami,undefined
[15] National Heart,undefined
[16] Lung,undefined
[17] and Blood Institute,undefined
[18] Harvard T. H. Chan School of Public Health,undefined
来源：
Journal of General Internal Medicine | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3797 / 3804
页数：7
相关论文
共 100 条
[1]  
Lewis CE(2021)Final Report of a Trial of Intensive Versus Standard Blood-Pressure Control N Engl J Med. 384 1921-1930
[2]  
Fine LJ(2014)Evidence-Based Risk Communication: a Systematic Review Ann Intern Med. 161 270-280
[3]  
Zipkin DA(2010)The Hazards of Hazard Ratios Epidemiology. 21 13-15
[4]  
Umscheid CA(2016)Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials J Clin Oncol. 34 1813-1819
[5]  
Keating NL(2011)The Use of Restricted Mean Survival Time to Estimate the Treatment Effect in Randomized Clinical Trials When the Proportional Hazards Assumption Is in Doubt Stat Med. 30 2409-2421
[6]  
Hernan MA(2013)Restricted Mean Survival Time: an Alternative to the Hazard Ratio for the Design and Analysis of Randomized Trials with a Time-to-Event Outcome BMC Med Res Methodol. 13 152-2385
[7]  
Trinquart L(2014)Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis J Clin Oncol. 32 2380-134
[8]  
Jacot J(2015)Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies Ann Intern Med. 163 127-233
[9]  
Conner SC(2014)Predicting the Restricted Mean Event Time with the Subject’s Baseline Covariates in Survival Analysis Biostatistics. 15 222-2126
[10]  
Porcher R(2020)Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve N Engl J Med. 383 2117-1991
12345678910